Measures · D12 in 2025 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing
Statin Use in Persons with Diabetes (SUPD)
Drug PlanMedication AdherenceSource: Prescription Drug Events
- What it measures
- To lower their risk of developing heart disease, most people with diabetes should take cholesterol medication. This rating is based on the percent of plan members with diabetes who take the most effective cholesterol-lowering drugs. Plans can help make sure their members get these prescriptions filled.
- How it's calculated
- This measure is defined as the percent of Medicare Part D beneficiaries 40-75 years old who were dispensed at least two diabetes medication fills on unique dates of service and received a statin medication fill during the measurement period. The percentage is calculated as the number of member-years of enrolled beneficiaries 40-75 years old who received a statin medication fill during the measurement period (numerator) divided by the number of member-years of enrolled beneficiaries 40-75 years old with at least two diabetes medication fills on unique dates of service during the measurement period (denominator). Beneficiaries are only included in the measure calculation if the first fill of their diabetes medication occurs at least 90 days before the end of the measurement year or end of the enrollment episode. The SUPD measure is adapted from the measure concept that was developed and endorsed by the PQA. See the medication list for this measure. The SUPD measure is calculated using the NDC lists updated by the PQA. The complete NDC lists, including diagnosis codes, are posted along with these technical notes.
- Data source
- Prescription Drug Event (PDE) data The data for this measure come from Prescription Drug Event (PDE) data submitted by drug plans to the CMS DDPS and accepted by the 2023 PDE submission deadline for annual Part D payment reconciliation with dates of service from January 1, 2023 – December 31, 2023. If the PDE edit results in the PDE being rejected by DDPS, then the PDE is not used in the Patient Safety measure calculations. If the PDE edit is informational and therefore, does not result in the PDE being rejected, then the PDE is used in the Patient Safety measure calculations. Reminder, CMS uses the term “final action” PDE to describe the most recently accepted original, adjustment, or deleted PDE record representing a single dispensing event. Original and adjustment final action PDEs submitted by the sponsor and accepted by DDPS prior to the 2023 PDE submission deadline are used to calculate this measure. PDE adjustments made post- reconciliation were not reflected in this measure. Additional data sources include the CME, the EDB, the CWF, and the EDS. The data cut off date for all the additional data sources listed below such as the CME, CWF, and EDS is determined by the same PDE submission deadline for the annual Part D payment reconciliation. • CME is used for enrollment information. • EDB is used to identify beneficiaries who elected to receive hospice care or with ESRD status (dialysis start and end dates within the measurement period). Due to CMS’s migration of the beneficiary database, including the EDB and CME, to the Amazon Web Services (AWS Cloud), equivalent EDB information to identify beneficiaries in hospice and with ESRD status is pulled from the CME beneficiary tables from the Integrated Data Repository (CME IDRC), sourced from the same upstream database. • CWF is used to identify exclusion diagnoses based on ICD-10-CM codes. • EDS is used to identify diagnoses based on ICD-10-CM codes.
- Measurement period
- 01/01/2023 – 12/31/2023
- Better when
- Higher
- Weight
- 1 (Process Measure)
- Star assignment
- Clustering
- Case-mix adjusted
- No
- In improvement measure
- Yes
- Used in CAI
- Yes
- Exclusions
Show
Contracts with 30 or fewer enrolled member-years (in the denominator). The following beneficiaries are excluded from the denominator if at any time during the measurement period: • Hospice enrollment • ESRD diagnosis or dialysis coverage dates • Rhabdomyolysis and myopathy • Pregnancy, Lactation, and fertility • Cirrhosis • Pre-Diabetes • Polycystic Ovary Syndrome- Notes
- Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the PQA medication or NDC lists, are excluded from CMS analyses. Also, the member- years of enrollment adjustment is made by CMS to account for partial enrollment within the benefit year. Enrollment is measured at the episode level, and inclusion in the measure is determined separately for each episode – i.e., to be included for a given episode, the beneficiary must meet the initial inclusion criteria for the measure during that episode. The measure is weighted based on the total number of member years for each episode in which the beneficiary meets the measure criteria. For instance, if a beneficiary is enrolled for a three-month episode, disenrolled for a six-month episode, reenrolled for a three-month episode, and meets the measure criteria during each enrollment episode, s/he will count as 0.5 member years in the rate calculation (3/12 + 3/12 = 6/12).
- Disaster policy
- Higher measure star (2024-2025) for contracts with 25% or more enrolled affected by 2023 disasters.
From the 2025 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 83 | 84.5 | +1.5 |
| 3★ | MA-PD | 87 | 89 | +2 |
| 4★ | MA-PD | 90 | 91 | +1 |
| 5★ | MA-PD | 94 | 95 | +1 |
| 2★ | PDP | 81 | 82.5 | +1.5 |
| 3★ | PDP | 83 | 83.5 | +0.5 |
| 4★ | PDP | 85 | 85.5 | +0.5 |
| 5★ | PDP | 87 | 88 | +1 |
2025 star distribution
Not rated: Plan too new to be measured (63); Not enough data available (62); No data available (27); Plan not required to report measure (5)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 83 % | >= 83 % to < 87 % | >= 87 % to < 90 % | >= 90 % to < 94 % | >= 94 % |
| 2027 | PDP | < 81 % | >= 81 % to < 83 % | >= 83 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2026 | MA-PD | < 81 % | >= 81 % to < 85 % | >= 85 % to < 89 % | >= 89 % to < 93 % | >= 93 % |
| 2026 | PDP | < 82 % | >= 82 % to < 83 % | >= 83 % to < 84 % | >= 84 % to < 86 % | >= 86 % |
| 2025 | MA-PD | < 81 % | >= 81 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 93 % | >= 93 % |
| 2025 | PDP | < 80 % | >= 80 % to < 83 % | >= 83 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2024 | MA-PD | < 81 % | >= 81 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 92 % | >= 92 % |
| 2024 | PDP | < 81 % | >= 81 % to < 83 % | >= 83 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2023 | MA-PD | < 80 % | >= 80 % to < 84 % | >= 84 % to < 86 % | >= 86 % to < 90 % | >= 90 % |
| 2023 | PDP | < 80 % | >= 80 % to < 82 % | >= 82 % to < 84 % | >= 84 % to < 86 % | >= 86 % |
| 2022 | MA-PD | < 76 % | >= 76 % to < 80 % | >= 80 % to < 84 % | >= 84 % to < 88 % | >= 88 % |
| 2022 | PDP | < 77 % | >= 77 % to < 79 % | >= 79 % to < 82 % | >= 82 % to < 84 % | >= 84 % |
| 2021 | MA-PD | < 77 % | >= 77 % to < 81 % | >= 81 % to < 83 % | >= 83 % to < 87 % | >= 87 % |
| 2021 | PDP | < 74 % | >= 74 % to < 79 % | >= 79 % to < 82 % | >= 82 % to < 85 % | >= 85 % |
| 2020 | MA-PD | < 74% | ? 74% to < 78% | ? 78% to < 81% | ? 81% to < 83% | ? 83% |
| 2020 | PDP | < 76% | ? 76% to < 78% | ? 78% to < 79% | ? 79% to < 83% | ? 83% |
| 2019 | MA-PD | < 72% | ? 72% to < 76% | ? 76% to < 80% | ? 80% to < 83% | ? 83% |
| 2019 | PDP | < 73% | ? 73% to < 77% | ? 77% to < 79% | ? 79% to < 82% | ? 82% |
Lowest-scoring contracts, 2025
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| H7779 American Health Advantage of Tennessee | Mitchell Family Office | 297 | 73 | 1 | 0 | 16 | 0% |
| H9489 Vermont Blue Advantage | Blue Cross Blue Shield of Michigan Mutual Ins. Co. | 0 | 73 | 1 | 0 | 16 | 0% |
| S5795 Arkansas Blue Medicare | USAble Mutual Insurance Company | 19,195 | 77 | 1 | 0 | 8 | 0% |
| R3175 UnitedHealthcare | UnitedHealth Group, Inc. | 0 | 75 | 1 | 0 | 14 | 0% |
| H6851 WellSense Health Plan | BMC Health System, Inc. | 4,226 | 75 | 1 | — | 14 | 0% |
| H3810 AllCare Advantage | AllCare Health, Inc. | 2,485 | 75 | 1 | 0 | 14 | 0% |
| H4754 PacificSource Medicare | PacificSource | 2,527 | 75 | 1 | 0 | 14 | 0% |
| H6743 ATRIO Health Plans | ATRIO Health Plans | 21,042 | 75 | 1 | 0 | 14 | 0% |
| H3708 American Health Advantage of Oklahoma | Mitchell Family Office | 549 | 75 | 1 | −1 | 14 | 0% |
| H4537 Wellcare | Centene Corporation | 2,251 | 76 | 1 | 0 | 13 | 1% |
| H1737 Health Alliance Medicare | The Carle Foundation | — | 76 | 1 | 0 | 13 | 1% |
| H4232 American Health Advantage of Utah | Mitchell Family Office | 296 | 76 | 1 | 0 | 13 | 1% |
| H1350 Blue Cross of Idaho | Gemstone Holdings, Inc. | 32,406 | 77 | 1 | 0 | 12 | 2% |
| H6586 Devoted Health | Devoted Health, Inc. | 7,033 | 77 | 1 | — | 12 | 2% |
| H3814 ATRIO Health Plans | ATRIO Health Plans | 1,997 | 77 | 1 | 0 | 12 | 2% |
| H9469 Simply Healthcare | Elevance Health, Inc. | — | 77 | 1 | — | 12 | 2% |
| H1304 Regence BlueShield of Idaho | Cambia Health Solutions, Inc. | 902 | 77 | 1 | 0 | 12 | 2% |
| S5609 Asuris Northwest Health | Cambia Health Solutions, Inc. | 279 | 78 | 1 | 0 | 7 | 2% |
| H2246 Select Health | Intermountain Health Care, Inc. | — | 78 | 1 | — | 11 | 3% |
| H8093 Georgia Health Advantage | Mitchell Family Office | 2,064 | 78 | 1 | 0 | 11 | 3% |
| H6830 Wellcare by Allwell | Centene Corporation | — | 78 | 1 | 0 | 11 | 3% |
| H3536 Anthem Blue Cross and Blue Shield | Elevance Health, Inc. | 0 | 78 | 1 | −1 | 11 | 3% |
| H5010 Asuris Northwest Health | Cambia Health Solutions, Inc. | — | 78 | 1 | −1 | 11 | 3% |
| H2582 UnitedHealthcare | UnitedHealth Group, Inc. | — | 78 | 1 | 0 | 11 | 3% |
| H6529 MyTruAdvantage | SIHO Holding, Inc. | 2,315 | 78 | 1 | −1 | 11 | 3% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D11 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2025 – 12/31/2025 | 1 | Prescription Drug Events |
| 2026 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2024 – 12/31/2024 | 1 | Prescription Drug Events |
| 2025 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2023 – 12/31/2023 | 1 | Prescription Drug Events |
| 2024 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2022 – 12/31/2022 | 1 | Prescription Drug Events |
| 2023 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2021 – 12/31/2021 | 1 | Prescription Drug Events |
| 2022 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2020 – 12/31/2020 | 3 | Prescription Drug Events |
| 2021 | D14 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2019 – 12/31/2019 | 3 | Prescription Drug Events |
| 2020 | D14 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2018 – 12/31/2018 | 1 | Prescription Drug Events |
| 2019 | D14 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2017 – 12/31/2017 | 1 | Prescription Drug Events |